June 28, 2023

The Honorable Patty Murray, Chair
The Honorable Susan Collins, Vice Chair
Senate Appropriations Committee
Washington, DC 20510

The Honorable Kay Granger, Chairwoman
The Honorable Rosa DeLauro, Ranking Member
House Appropriations Committee
Washington DC, 20515

by electronic delivery

Dear Chair Murray, Vice Chair Collins, Chairman Granger and Ranking Member DeLauro:

As you continue the essential work to develop and pass Fiscal Year 2024 (FY24) appropriations bills, we write to reiterate support for priorities communicated earlier this year by the health, aging, and science advocacy community.

Since well prior to passage of the landmark National Alzheimer’s Project Act in 2010, advocates have implored Congress that Alzheimer’s disease was the only cause of death among the top 10 without an effective means of prevention or treatment. Thanks to sustained, robust, and effective investments by Congress and the private sector, as soon as this summer, there may be widespread access to the first disease-modifying treatment to slow the progression of Alzheimer’s disease. Your pivotal investments are working. Now there is even greater urgency to build on this watershed moment with an unrelenting commitment of essential funding to advance the science to even more effective treatments for Alzheimer’s disease and related disorders along with strengthening the programmatic supports imperative to improving quality of life for people with dementia and their caregivers.

We sincerely thank you for recognizing and decisively responding to the challenges of Alzheimer’s disease and other forms of dementia (e.g. cerebrovascular disease, Lewy body dementia, frontotemporal degeneration, and Creutzfeldt-Jakob disease) by passing Fiscal Year 2023 appropriations with a historic funding increase for Alzheimer’s research. We applaud your continued determination to seize the enormous opportunities for America by investing in the science, care, and support required to overcome these challenges and for recognizing the consequences if we fail to continue acting with the required urgency. Doing so is a national priority, economic and budgetary necessity, health and moral imperative.

We respectfully encourage you to continue the momentum toward the National Alzheimer’s Plan goals and your own commitment to advancing science, care and support, and public health. Specifically, we request that the FY24 appropriations bills include at least the following minimum levels:

- a $321 million increase for National Institutes of Health (NIH) research on Alzheimer’s disease and other forms of dementia to accelerate progress as articulated in the Bypass Budget Proposal for FY24
• a $3.5 billion increase (to $51 billion) for NIH, allowing its base budget to keep pace with the biomedical research and development price index (BRDPI) and maintaining meaningful growth of nearly 5%. Funding for ARPA-H should supplement, rather than supplant, the essential foundational investment in the NIH.

• A $60 million increase for the BRAIN Initiative

• A $372 million increase for the FDA, in addition to funds included in the 21st Century Cures Act for targeted initiatives

• Double funding for Older Americans Act (OAA) and other aging programs and services
  o a $6.5 million increase for the ACL Alzheimer’s Disease Program
  o a $35 million increase for the HRSA geriatrics workforce programs
  o a $5 million increase for the DoJ Missing Alzheimer’s Disease Alert Program

• $60 million for the CDC’s Alzheimer’s Disease and Healthy Aging Program (ADHAP) to continue BOLD Act implementation, expand the CDC Healthy Brain Initiative road map for state and national partnerships, and reduce dementia risk through brain health promotion

Additionally, we support sustained and robust funding for Federally Qualified Health Centers (FQHCs).

We also support appropriations report language to advance accomplishing goals of the National Alzheimer’s Plan.

There are few more compelling or complex issues to confront our aging society, now and over the coming decades, than Alzheimer’s disease and other forms of dementia. These neurodegenerative conditions impose enormous costs to our nation’s health, prosperity, and social fabric, costs that are skyrocketing. Based on the National Institute on Aging’s Health and Retirement Study (HRS), we know that the health system costs of caring for people with dementia in the United States are comparable to, and perhaps greater than, those for heart disease and cancer. A 2015 analysis of HRS data revealed that average per-person health care spending in the last five years of life for people with dementia was more than $250,000 -- 57 percent greater than costs associated with death from other diseases including cancer and heart disease. Those costs continue to climb and are unsustainable for families, public and private insurers, and our nation’s economy.

Currently, more than 6.7 million Americans are living with dementia, with combined healthcare and long-term care costs of $345 billion. Taxpayers foot about 64% of that bill -- $222 billion -- directly through the Medicare and Medicaid programs. Individuals with dementia and their families pay out of pocket 25% of the cost, $87 billion. More than 11 million Americans provide unpaid care for someone with dementia, resulting in additional
healthcare and economic costs. Today, as another person develops the disease every 65 seconds, Alzheimer’s and other forms of dementia impose an economic cost nearing $690 billion in public and private expenditures along with uncompensated caregiving. By 2050, someone in the United States will develop the disease every 33 seconds with as many as 12.7 million Americans living with dementia. This explosive growth will cause direct costs to increase from $345 billion in 2023 to approximately $1 trillion in 2050 (in 2022 dollars) and the hidden costs of uncompensated caregiving to become even more staggering.v

Alzheimer’s disease contributes to the deaths of more than 500,000 Americans each year. Alzheimer’s disease is the third leading cause of death in the United Statesvi and — despite a powerful body of evidence for risk-reduction strategies,vii which is being expanded with significant NIH investmentsviii — the only one among the top 10 for which there is not yet a proven means of prevention, disease modification or cure.ix One third of older Americans dies with Alzheimer’s disease or another form of dementia.x

Advancing Science

We support a $321 million increase for National Institutes of Health (NIH) research on Alzheimer’s disease and other forms of dementia to accelerate progress as proposed in the NIH FY24 Bypass Budget.xi The choice before our nation is not whether to pay for dementia -- we are paying dearly. The question is whether we will emulate the sustained investment strategies that have led to remarkable progress in fighting other leading causes of death and achieve similar breakthroughs, or spend trillions to care for tens of millions of people. A modernized and more robust research portfolio can help America prevent this catastrophe and move us closer to achieving our national goal of preventing and effectively treating dementia by 2025.xii

Due to leadership and direction from Congress, the Department of Health and Human Services (HHS) continues to increase prioritization of Alzheimer’s disease and other forms of dementia. The publicly appointed members of the Advisory Council on Alzheimer’s Research, Care, and Services have generated thoughtful and catalytic recommendations for the annual update to the National Plan to Address Alzheimer’s Disease. There is heightened focus on improving care for people with advanced dementia.xiii The Food and Drug Administration (FDA) is encouraging new research avenues, clarifying regulatory approval pathways,xiv and reviewing products to modify disease pathology, clinical progression, and the most heart-breaking symptoms of dementia. Congressional appropriations committees and NIH have moved mountains to create additional resources, public-private partnerships, and a culture of urgency. Across NIH, institutes are advancing promising research into Alzheimer’s disease and other forms of dementia to: understand genetic risk factors; address health disparities among women, communities of color, and persons with intellectual and developmental disabilities; understand Down syndrome’s relationship to Alzheimer’s disease; pursue cutting-edge trials aimed at preventing or substantially slowing disease progression by administering treatments much earlier in the disease process; and improve quality of life for people with dementia and their caregivers.xv NIH is demonstrating strong progress as reflected in the AD+ADRD (Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias) Research Implementation Milestones database.xvi NIH and its partners are hard at work implementing the National Strategy for Recruitment and Participation in Alzheimer’s and Related Dementias Clinical Research,xvii engaging broad segments of the public in the Alzheimer’s and related dementias research enterprise, with a particular focus on making research participants more accurately reflect intended
beneficiaries of breakthroughs. The progress has been important but incomplete in diversifying the scientific workforce, the pool of clinical trial participants, and the nature of the specific research projects to remedy the deep and disturbing health disparities that drive Alzheimer’s disease and other forms of dementia. In FY24, the National Institute on Aging (NIA) plans to advance research to improve the diagnosis, treatment, and care of those living with dementia by identifying and testing new drug candidates, advancing comprehensive models of care, developing novel biomarkers for use as screening tests and to monitor treatment response, exploring disease risk and protective factors, and improving the understanding of the role of genetics and other disease mechanisms.xviii

We support the recommendation from the Ad Hoc Group on Medical Research to appropriate at least $51 billion for the NIH’s base program level, with funding for the Advanced Research Projects Agency for Health (ARPA-H) to supplement, rather than supplant, this core investment in NIH. This $51 billion core NIH investment would continue a trajectory of steady and predictable annual increases – allowing meaningful base budget growth above inflation that would expand NIH’s capacity to support promising science in all disciplines – and would ensure that the Innovation Account supplements the agency’s base budget, as intended, through dedicated funding for specific programs.

We support the recommendation from the American Brain Coalition for a $60 million increase for the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative. Originally created in 2013, the BRAIN Initiative is revolutionizing our understanding of the human brain to better develop treatments and cures for neurologic diseases, including Alzheimer’s and other forms of dementia. This multidisciplinary collaboration (including the NIH, FDA, DARPA and IARPA, xix along with private partners) is working to map circuits of the brain, measure electrical and chemical activity, and understand how their interplay creates unique cognitive and behavioral capabilities. To date, the BRAIN Initiative has supported more than 1,300 awards totaling more than 3 billion,xx resulting in research that has made significant advances in important technologies such as brain imaging.xxi The ongoing commitment to fund this program will continue the roll out of three large transformative projects that will build a comprehensive atlas of cell types in the human brain, develop and scale up the tools necessary to complete a micro-connectivity map of an entire mammalian brain, and provide tools for precision access to the identified cell types to allow interrogation and modulation of neural circuits. Together, these tools will enable the eventual development of novel interventions—including molecular and gene-editing therapies—for human circuit disorders.xxii

We support the recommendation from the Alliance for a Stronger FDA for a $372 million increase for the FDA to meet the most pressing needs in medical products and food safety programs.xxiii Funding would strengthen FDA systems that guide and support agency decision-making and stimulate innovation for medical products, including improvements in drug and device manufacturing, advances in the use of real-world evidence in medical product development, revisions to the regulatory framework for digital health technology, enhancements to research on rare diseases such as less common forms of dementia, and new systems that could speed the introduction of cost-saving generic drugs.

Strengthening Quality of Life

Until science delivers effective means to prevent, slow, or cure dementia, families and friends along with health care providers rely on programs to protect their own well-being as
they help persons with dementia to remain independent and in the community while delaying placement in institutional settings.

We support recommendation from the Leadership Council of Aging Organizations (LCAO) to double funding for Older Americans Act (OAA) and other aging programs and services. These investments are relatively small but crucial complements to vastly larger Medicaid and Medicare expenditures to protect and promote the wellbeing of people living with dementia and their caregivers along with other older adults. As urgently as resources are needed to enable scientific breakthroughs, millions of Americans currently living with dementia and their family caregivers deserve strengthened commitments to programs to protect and enhance their quality of life. The World Health Organization has noted that dementia is among the leading causes of disability and dependence among older people. Federal initiative and programs have a vital role in helping people receive a diagnosis so they know what they are facing, can begin disability and care planning processes, maintain independence as long as possible, and – for people with younger onset dementia – seek appropriate workplace accommodations. We commend your work to ensure that OAA programs and services were sustained during the worst of the pandemic. In FY24, expansion of aging programs and services would be instrumental to achieving the National Plan’s goals to enhance care quality, efficiency, and supports for people living with dementia and their caregivers.

We support a $6.5 million increase for the ACL Alzheimer’s Disease Program. The Administration for Community Living (ACL) Alzheimer’s Disease Program Initiative (ADPI) supports and promotes the development and expansion of dementia-capable home and community-based service long-term services and support systems in states and communities. As American Indians and Alaska Natives communities experience higher rates of dementia, we applaud the recent ADPI grant specific to development of dementia capability in Indian Country. We encourage its funding and continuation in future years. ADPI delivers cutting-edge programs that meet the needs of individuals and caregivers managing dementia. Part of those resources support ACL’s National Alzheimer’s and Dementia Resource Center (NADRC). NADRC provides technical assistance to ACL’s grantees that build dementia-capable systems to better identify and support people with dementia living in the community and improve training for dementia caregivers who experience considerable stress and depression. Many of the programs are geared towards at-risk dementia populations, such as those who live alone, those with disabilities (including those with intellectual disabilities), and those who reside in rural, poor, and minority communities. NADRC also produces dementia-related toolkits and provides technical assistance and webinars on Alzheimer’s and other form of dementia to the public.

We support a $35 million increase for the geriatrics education and training programs under Title VII of the Public Health Services (PHS) Act. The Geriatrics Workforce Enhancement Program (GWEP) and the Geriatrics Academic Career Awards (GACAs), administered by the Health Resources and Services Administration (HRSA), are the only federal mechanism for supporting geriatrics health professions education and training. Sustained and enhanced investment will ensure that these critical resources are maximally deployed to serve older adults nationwide. GWEP awardees educate and engage the broader frontline workforce, including family caregivers, and focus on improving quality of care delivered to older adults. An important GWEP component is developing academic-primary care-community-based partnerships to address gaps in older adults’ health care while transforming clinical training environments into integrated geriatrics and primary care sites/systems that become age-friendly health systems and dementia-friendly communities.
An essential complement to the GWEP, the GACA program builds a pipeline of individuals with academic and research expertise who become leaders in their fields and enhance the educational or research capacity at the grantee’s institution. The proposed increases would enable every state to have a GWEP program and ensure that more rural and underserved areas of the country have access to geriatrics training and expertise to expand the capacity of the existing health care delivery and caregiving workforce. The increases for GACAs would ensure a larger and geographically more diverse pipeline of geriatrics research and training expertise with needed incentives and resources to grow the field.

We support a $5 million increase for the Department of Justice (DoJ) Missing Alzheimer’s Disease Patient Alert Program, which provides grants for training and technology that help first responders locate people living with Alzheimer’s disease or autism who wander and become lost. The program saves lives, strengthens the capacity of search and rescue programs to respond to other community needs, and allows local first responders to conserve both time and money. The program’s strong track record, along with rapid growth in the number of people living with dementia and the program’s expansion to include services for people living with autism, merit and require substantial addition resources to better serve states and communities nationwide.

Promoting Public Health

We support $60 million for the CDC’s Alzheimer’s Disease and Healthy Aging Program (ADHAP) to continue BOLD Act implementation, expand the CDC Healthy Brain Initiative roadmap for state and national partnerships, and reduce dementia risk through brain health promotion.

The ADHAP is the only place within the CDC specifically dedicated to promoting the health of older adults through dementia risk-reduction interventions (e.g. smoking cessation, exercise, education) and across chronic conditions that heighten risk for dementia (e.g. hypertension, hearing loss, depression, traumatic brain injury, diabetes, obesity). The ADHAP also is the central locus for addressing health equity challenges across chronic conditions that share these common risk factors. Yet, last year, total funding for the ADHAP’s vital work represented only approximately 0.25% of the overall CDC budget.

Specifically, the $60 million funding level would support the CDC ADHAP’s work to:

• strengthen programs that reduce risk, promote health equity, and support populations with a high burden of Alzheimer’s disease and related forms of dementia
• build public health infrastructure through the BOLD Act and Healthy Brain Initiative
• expand capacity in state, tribal and territorial public health departments to promote the health of older adults within an age-friendly public health system
• expand healthy aging work to include coordinating healthy aging efforts across the agency and implementing a public-private initiative to reduce dementia risk
• fund applied research and translation for public health practice
• support public health strategies addressing the social determinants of health that contribute to disparities in healthy aging and brain health.

As part of this overall ADHAP funding, we support $35 million for CDC to continue implementing the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer’s Act (Pub. L. 115 – 406). Under the law, Congress directed CDC to strengthen the public
health infrastructure nationwide by implementing effective Alzheimer's interventions focused on public health priorities including increasing early detection and diagnosis, reducing modifiable risk, and preventing avoidable hospitalizations. We commend your work to fund CDC’s ADHAP its BOLD Act work to support implementation of the Healthy Brain Aging Road Map. Congress authorized $100 million over five years so that CDC would have the necessary resources to establish Alzheimer's and Related Dementias Public Health Centers of Excellence, provide funding to state, local, and tribal public health departments, and increase data analysis and timely reporting.

Increased funding also would support a significant increase for the CDC’s long-standing and successful Healthy Brain Initiative, which is implementing its 2018-2023 Healthy Brain Aging Road Map (and companion Road Map for Indian Country) to ramp up the nation’s public health capacity in addressing dementia. The Road Map is advancing strategies to reduce lifestyle risk factors, improve detection and diagnosis, strengthen community supports for people with dementia and their families, and redress health disparities. The next Healthy Brain Aging Road Map is anticipated to be released this summer and will launch an even more ambitious phase of our nation’s public health response but to reduce the risk of dementia and to improve quality of life for those who are living with dementia.

**We support sustained and robust funding for Federally Qualified Health Centers (FQHCs).** The FQHCs help address cultural, linguistic, and other barriers to care by delivering coordinated and comprehensive primary and preventive services – helping to reduce health disparities in medically-underserved communities across the nation. Leveraging the capacity of these innovative, high quality, community-based, and trusted providers is an important way to advance health equity while reducing the burden of dementia on the individuals, families, communities, the healthcare system, the federal budget and national economy.

**Appropriations Report Language**

We also support appropriations report language to advance accomplishing goals of the National Alzheimer's Plan and request that the following be included:

- **Health Resources and Services Administration (HRSA), Community Health Centers (CHC)**

  Unfortunately, little is known about people with Alzheimer's disease and related forms of dementia served by CHCs and look-alikes in the CHC program due to the lack of available data. Data is essential to understanding the level of need, resources, training and challenges needed to keep people currently served in the CHC programs to continue as they age. The Committee strongly encourages HRSA to include Alzheimer's and related Dementia I-10 codes in the Uniform Data Collection System.

- **Health Resources and Services Administration (HRSA)**

  The Committee urges HRSA to establish a Brain Health Equity initiative to help drive the integration of brain health services into the workflow of primary care delivery that reaches underserved populations served by Federally Qualified Health Centers and look-alikes.
• Centers for Disease Control and Prevention (CDC) Alzheimer’s Disease and Healthy Aging Program

The Committee is encouraged by research demonstrating the positive impact of risk reduction on dementia prevalence and commends the Secretary for updating the National Alzheimer’s Plan to reflect the latest science. To ensure high burden populations are reached, the Committee directs CDC to increase capacity to reach populations disproportionately burdened by Alzheimer’s Disease — including, but not limited to Black/African American, Latino/Hispanic, American Indian/Native Alaskan, Down Syndrome, and rural populations — through public health promotion and workforce development by increasing Healthy Brain Initiative grants from $5.5 million to $10 million.

Thank you for considering our views and for your commitment to overcoming Alzheimer’s disease and other forms of dementia. For any questions or additional information about this legislation or other policy issues, please contact Ian Kremer, executive director of Leaders Engaged on Alzheimer's Disease (the LEAD Coalition),*** ikremer@leadcoalition.org or (571) 383-9916.

Sincerely,

Abe’s Garden Community  
Acadia Pharmaceuticals Inc  
Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD)  
ACCSES – The Voice of Disability Service Providers  
ACMCRM Arachnoiditis & Chronic Meningitis Collaborative Research Network  
ActivistsAgainstAlzheimer’s Network  
ADvancing States  
African American Network Against Alzheimer’s  
Nimit Agarwal MD (University of Arizona, Department of Medicine, Division of Geriatric Medicine*)  
AgeneBio  
AgeWell Collaboratory of Drexel University  
Neelum T. Aggarwal, MD (Rush University Medical Center*)  
Aging and Memory Disorder Programs, Howard University  
Aging Life Care Association®  
Paul S. Aisen, MD (Keck School of Medicine of USC, Alzheimer’s Therapeutic Research Institute*)  
Benedict C. Albensi, PhD, BCMAS, CRQM (Nova Southeastern University*)  
Ricardo F. Allegri MD, PhD (School of Medicine, Universidad de Buenos Aires*)  
Alliance for Aging Research  
Alliance for Patient Access  
Michael L. Alosco, PhD (Alzheimer’s Disease Research Center, Boston University Chobanian & Avedisian School of Medicine*)  
Alzheimer’s Association  
Alzheimer’s Disease Resource Center, Inc. (ADRC)  
Alzheimer’s Drug Discovery Foundation  
Alzheimer’s Foundation of America
Alzheimer's Impact Movement (AIM)
Alzheimer's Los Angeles
Alzheimer's New Jersey
Alzheimer's Orange County
Alzheimer's San Diego
Alzheimer's Tennessee
Takashi Amano, PhD, MSW (Rutgers University Newark*)
AMDA – The Society for Post-Acute and Long-Term Care Medicine
American Academy of Neurology
American Association for Geriatric Psychiatry
American Brain Coalition
American College of Preventive Medicine (ACPM)
American Federation for Aging Research (AFAR)
American Geriatrics Society
American Medical Women's Association
American Society for Biochemistry and Molecular Biology
American Society of Consultant Pharmacists (ASCP)
American Society on Aging
Halima Amjad, MD, PhD, MPH (Johns Hopkins University*)
Edward F. Ansello, Ph.D. (Virginia Commonwealth University*)
Brian S. Appleby, M.D. (Case Western Reserve University School of Medicine*)
María Aranda, PhD (USC Edward R. Roybal Institute on Aging*)
Argentum | Expanding Senior Living
Jalayne J. Arias, JD, MA (Georgia State University, School of Public Health*)
Association of California Caregiver Resource Centers (ACCRC)
Association of Population Centers
Athira Pharma, Inc.
Alireza Atri, MD, PhD (Banner Sun Health Research Institute*)
Rhoda Au, Ph.D. (Boston University Chobanian & Avedisian School of Medicine and Public Health*)
Autistic Women & Nonbinary Network —AWN
Laurie Badzek, LLM, JD, MS, RN, FNAP, FAAN (Penn State Ross and Carol Nese College of Nursing, Tressa Nese and Helen Diskevich Center of Geriatric Nursing Excellence*)
Laura D. Baker, PhD (Wake Forest University School of Medicine*)
The Balm In Gilead, Inc.
Banner Alzheimer's Institute
Banner Health
David M. Bass, PhD (Benjamin Rose Institute on Aging*)
Baylor Scott & White Health
Maryam Beigi, MD (Mary S. Easton Center for Alzheimer's Disease Research at UCLA*)
Andrew R. Bender, Ph.D. (Michigan State University*)
Benjamin Rose Institute on Aging
Tammie L.S. Benzinger, M.D., Ph.D. (Washington University School of Medicine in St. Louis*)
Biogen
B'nai B'rith International
Marie Boltz, PhD, GNP-BC, FGSA, FAAN (Penn State College of Nursing*)
Soo Borson MD (USC Keck School of Medicine*)
Nicole Bouranis PhD (Drexel University College of Nursing and Health Professions*)
Malaz A. Boustani MD, MPH, Indiana University Center for Health Innovation and Implementation Science*

Adam L. Boxer, MD, PhD (Department of Neurology, University of California, San Francisco*)

Andrea Bozoki, MD, FAAN (University of North Carolina, Chapel Hill*)

The Brain Donor Project

James Brewer, M.D., Ph.D. (UC San Diego and Alzheimer’s Disease Cooperative Study*)

Bridge Builder Strategies

BrightFocus Foundation

Brookdale Senior Living Inc.

Danielle Goldfarb Cabral, MD (University of Arizona College of Medicine*)

Ismael Calandri MD (University of Buenos Aires*)

Christopher M. Callahan, MD (Indiana University Center for Aging Research*)

Caregiver Action Network

CARE Research Center, Massachusetts General Hospital

CaringKind, The Heart of Alzheimer’s Caregiving

Maria Torroella Carney, MD, FACP (Northwell Health and Zucker School of Medicine at Hofstra/Northwell*)

Centene

Center for Alzheimer Research and Treatment, Harvard Medical School

Center for BrainHealth at The University of Texas at Dallas

Center to Advance Palliative Care

Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, UNLV

Marianne Chanti-Ketterl, PhD, MSPH (Duke-UNC Alzheimer’s Disease Research Center*)

Sandra Bond Chapman, PhD (Center for BrainHealth at The University of Texas at Dallas*)

Joshua Chodosh, MD, MSHS, FACP (NYU Grossman School of Medicine*)

Urvika Choksey, MD (Yale School of Medicine*)

ClergyAgainstAlzheimer’s Network

Cleveland Clinic Lou Ruvo Center for Brain Health, Nevada

Carolyn K Clevenger, DNP, GNP-BC, AGPCNP-BC, FAANP, FGSA, FAAN (Emory University*)

CNS Innovations

Coalition of Wisconsin Aging and Health Groups

The Coelho Center for Disability Law, Policy and Innovation

Cognitive Dynamics Foundation

Ann D. Cohen, PhD (Department of Psychiatry, University of Pittsburgh, School of Medicine*)

Corium

Tara A. Cortes PhD, RN, FAAN, FGSA (NYU Rory Meyers College of Nursing, The Hartford Institute for Geriatric Nursing*)

Suzanne Craft, PhD (Wake Forest School of Medicine*)

Creutzfeldt-Jakob Disease Foundation

Jeffrey Cummings, MD, ScD (University of Nevada Las Vegas*)

Lenise Cummings-Vaughn, MD (Washington University School of Medicine*)

Cure Alzheimer’s Fund

CurePSP

Kirk R. Daffner MD, FAAN (Brigham and Women’s Hospital, Harvard Medical School*)

Darmiyan
Walter Dawson, Dphil (Oregon Health & Science University*)

Steven T. DeKosky, MD, FACP, FANA, FAAN (University of Floriday College of Medicine*)

Dementia Alliance International

Dementia Alliance of North Carolina

Dementia Palliative Education Network

DigiCARE Realized Inc.

Elizabeth Disbrow, PhD (LSU Health Shreveport Center for Brain Health*)

Michael C Donohue, PhD (Keck School of Medicine of USC *)

N. Maritza Dowling PhD (The George Washington University School of Nursing*)

Drexel University College of Nursing and Health Professions

Easterseals

Eisai, Inc.

The Emory Goizueta Alzheimer's Disease Research Center

Fayron Epps, PhD, RN, FGSA, FAAN (Emory University, Nell Hodgson Woodruff School of Nursing*)

Gary Epstein-Lubow, MD (Alpert Medical School of Brown University & Brown University School of Public Health*)

Anne Fabiny, MD (University of California, San Francisco*)

Faith United Against Alzheimer's Coalition

Family Caregiver Alliance

D. Luke Fischer, MD, PhD (Weill Institute for Neurosciences, University of California, San Francisco*)

Concetta Forchetti MD, PhD (Department of Neurology, Northwestern University Feinberg School of Medicine*)

Brent P. Forester, MD, MSc (Tufts University School of Medicine*)

Richard H. Fortinsky, PhD (UConn Center on Aging, University of Connecticut School of Medicine*)

Frank & Barbara Broyles Legacy Foundation

Fujirebio

Seth A. Gale, M.D. (Brigham and Women's Hospital, Harvard Medical School*)

Michela Gallagher, PhD (Johns Hopkins University School of Medicine*)

Sam Gandy, MD, PhD (Icahn School of Medicine at Mount Sinai*)

Joseph E. Gaugler, PhD (School of Public Health, University of Minnesota*)

David S. Geldmacher, MD, FACP (University of Alabama at Birmingham School of Medicine*)

Genentech

Genetic Alliance

Daniel R. George, Ph.D, M.Sc (Penn State College of Medicine*)

Georgetown University Medical Center Memory Disorders Program

Gerontological Advanced Practice Nurses Association

The Gerontological Society of America

Thomas M. Gill, M.D. (Yale School of Medicine*)

Laura Gillen, MS (McDaniel College*)

Meredith Gilliam MD MPH (University of North Carolina*)

Laura N. Gitlin, PhD (Drexel University, College of Nursing and Health Professions*)

G. Peter Gliebus, MD, FAAN (Drexel University College of Medicine*)

Global Alzheimer's Platform Foundation

Global CEO Initiative on Alzheimer's Disease

Global Coalition on Aging
Zaven S. Khachaturian, PhD (Johns Hopkins University*)
Vikram Khurana, MD, PhD (Brigham and Women’s Hospital, Harvard Medical School*)
Amy J.H. Kind, MD, PhD (University of Wisconsin School of Medicine and Public Health*)
William E. Klunk, M.D., Ph.D. (University of Pittsburgh*)
Rada Koldamova MD, PhD (School of Public Health, University of Pittsburgh*)
Walter A. Kukull, PhD (School of Public Health, University of Washington*)
Latino Alzheimer’s and Memory Disorders Alliance
LatinosAgainstAlzheimer’s
Layton Aging and Alzheimer’s Disease Center, Oregon Health & Science University
LeadingAge
Edward B. Lee, M.D., Ph.D. (Perelman School of Medicine at the University of Pennsylvania*)
Cynthia A. Lemere, PhD (Brigham & Women’s Hospital; Harvard Medical School*)
Allan Levey, MD, PhD (Emory University School of Medicine*)
Lewy Body Dementia Association
Life Molecular Imaging
Jennifer Lingler PHD, MA, CRNP, FAAN (University of Pittsburgh, School of Nursing*)
Linked Senior, Inc
Lei Liu, MD PhD, (Brigham and Women’s Hospital, Harvard Medical School*)
Livpact Inc.
Marissa Natelson Love, MD (Division of Memory Disorders and Behavioral Neurology, University of Alabama at Birmingham*)
LuMind IDSC Foundation
Lundbeck Pharmaceuticals, LLC
Lupus and Allied Diseases Association, Inc.
Kostas Lyketsos, M.D., M.H.S. (Johns Hopkins Memory and Alzheimer’s Treatment Center*)
Yannick Marchalant, Ph.D. (Central Michigan University*)
Beth Marks, PhD, RN, FAAN (University of Illinois at Chicago*)
David X. Marquez, PhD (Department of Kinesiology and Nutrition, University of Illinois at Chicago*)
Massachusetts Alzheimer’s Disease Research Center (Harvard Medical School, Mass General Brigham)
Donovan Maust, MD, MS (University of Michigan Medical School*)
Eric McDade, DO (Washington University School of Medicine*)
Medicare Rights Center
Michigan State University Alzheimer’s Alliance
Milken Institute Alliance to Improve Dementia Care
Brienne Miner, MD MHS (Yale University School of Medicine*)
Minnesota Association of Area Agencies on Aging
MLD Foundation
Vincent Mor, PhD (Brown University, School of Public Health*)
David G. Morgan, PhD (Michigan State University*)
Darby Morhardt, PhD, LCSW (Northwestern University Feinberg School of Medicine*)
Mount Sinai Center for Cognitive Health
Catherine Mummery, MBBS PhD (University College London*)
Aanand Naik, MD (University of Texas Health Houston*)
National Alliance for Caregiving
National Asian Pacific Center on Aging
National Association of Activity Professionals
National Academy of Elder Law Attorneys
National Association of Social Workers (NASW)
National Association of State Long-Term Care Ombudsman Programs (NASOP)
National Caucus and Center on Black Aged, Inc. (NCBA)
National Certification Council for Activity Professionals
National Committee to Preserve Social Security and Medicare
National Consumers League
National Consumer Voice for Quality Long-Term Care
National Council for Behavioral Health
National Down Syndrome Society
National Hartford Center of Gerontological Nursing Excellence
National Hispanic Council On Aging (NHCOA)
National Indian Council on Aging (NICOA)
National Minority Quality Forum
National Prion Disease Pathology Surveillance Center
National Task Group on Intellectual Disabilities and Dementia Practices
NFL Neurological Center
Noah Homes
Thomas O. Obisesan, MD, MPH (Howard University Hospital*)
The Ohio Council for Cognitive Health
Organic Acidemia Association
Rik Ossenkoppele PhD (Alzheimer center | Amsterdam University Medical Center*)
Otsuka America Pharmaceutical Inc.
Miguel A. Pappolla, MD, PhD (University of Texas Medical Branch*)
Van Ta Park, PhD, MPH (University of California, San Francisco*)
Monica W. Parker, MD (Goizueta Alzheimer's Disease Research Center, Emory University*)
Partnership to Fight Chronic Disease
Patients Rising Now
Pat Summitt Foundation
Penn Program on Precision Medicine for the Brain (P3MB)
Penn State Ross and Carol Nese College of Nursing, Tressa Nese and Helen Diskevich Center of Geriatric Nursing Excellence
Pentara Corporation
Planetree International, Inc.
Population Association of America
Anton P. Porsteinsson, M.D. (University of Rochester School of Medicine and Dentistry*)
Positrigo AG
Katherine Possin, PhD (University of California San Francisco, Memory and Aging Center*)
Daniel C. Potts, MD, FAAN (University of Alabama College of Community Health Sciences*)
Melinda C. Power, ScD (Milken Institute School of Public Health, George Washington University*)
Daniel Z. Press, MD (Harvard Medical School*)
Prevent Alzheimer's Disease 2020
PXE International
Pierre N. Tariot, MD (University of Arizona College of Medicine*)
Carmela Tartaglia, M.D., FRCPC (Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto*)
David B. Teplow Ph.D. (Department of Neurology, David Geffen School of Medicine at UCLA*)
Texas Rare Alliance
The Association for Frontotemporal Degeneration
The Evangelical Lutheran Good Samaritan Society
The Memory Impairment and Neurodegenerative Dementia (MIND) Center, University of Mississippi Medical Center
Megan Thomas Hebdon, PhD, DNP, RN, NP-c (University of Texas at Austin School of Nursing*)
Trellis/ACT on Alzheimer’s
Geoffrey Tremont, Ph.D., ABPP-CN (Alpert Medical School of Brown University*)
Elena Tsoy, PhD (Department of Neurology, University of California, San Francisco*)
R. Scott Turner, MD, PhD (Georgetown University Memory Disorders Program*)
UCLA Mary S. Easton Center for Alzheimer's Disease Research, David Geffen School of Medicine
University of Minnesota Center for Healthy Aging and Innovation (CHAI)
University of Rochester Alzheimer’s Disease Care, Research and Education Program (AD-CARE)
UsAgainstAlzheimer’s, LEAD Coalition co-convener
USAGeorgia
USC Edward R. Roybal Institute on Aging
Ipsit Vahia, MD (Mclean Hospital, Harvard Medical School*)
Lawren VandeVrede, MD/PhD (University of California, San Francisco*)
Christopher H. van Dyck, MD (Alzheimer's Disease Research Center, Yale School of Medicine*)
Linda J. Van Eldik, PhD (Sanders-Brown Center on Aging and Alzheimer's Disease Research Center, University of Kentucky*)
VeteransAgainstAlzheimer’s
Virginia Center on Aging
Anand Viswanathan, MD, PhD (Massachusetts General Hospital and Alzheimer's Disease Research Center*)
Voices of Alzheimer’s
Stella L. Volpe, PhD, RDN, ACSM-CEP, FACSM (Virginia Tech*)
Volunteers of America, LEAD Coalition co-convener
Keith Vossel, MD, MSc (Mary S. Easton Center for Alzheimer's Disease Research, David Geffen School of Medicine at UCLA)
Victoria Walker, MD CMD (Sanford School of Medicine, University of South Dakota*)
Qing Wang Ph.D. (Washington University in St. Louis, School of Medicine*)
David A. Weidman, MD, FAAN (Banner Alzheimer's Institute*)
Carol J. Whitlatch, PhD (Benjamin Rose Institute on Aging*)
Nancy Wilson, MA LCSW (Baylor College of Medicine*)
Jennifer Wolff, PhD (Johns Hopkins Bloomberg School of Public Health*)
David A. Wolk, MD, FAAN (Alzheimer’s Disease Research Center, Perelman School of Medicine at the University of Pennsylvania*)
*Affiliations of individual researchers are for identification purposes only and do not necessarily represent the endorsement of affiliated institutions.*


vi [http://www.neurology.org/content/early/2014/03/05/WNL.0000000000000240](http://www.neurology.org/content/early/2014/03/05/WNL.0000000000000240)


ix [http://www.neurology.org/content/early/2014/03/05/WNL.0000000000000240](http://www.neurology.org/content/early/2014/03/05/WNL.0000000000000240)


xvi [https://www.nia.nih.gov/research/milestones](https://www.nia.nih.gov/research/milestones)


xix [https://braininitiative.nih.gov](https://braininitiative.nih.gov)
Leaders Engaged on Alzheimer’s Disease (the LEAD Coalition) is a diverse national coalition of member organizations including patient advocacy and voluntary health non-profits, philanthropies and foundations, trade and professional associations, academic research and clinical institutions, and home and residential care providers, large health systems, and biotechnology and pharmaceutical companies. The LEAD Coalition works collaboratively to focus the nation’s strategic attention on dementia in all its causes -- including Alzheimer’s disease, vascular disease, Lewy body dementia, and frontotemporal degeneration -- and to accelerate transformational progress in detection and diagnosis, care and support, and research leading to prevention, effective treatment, and eventual cure. One or more participants may have a financial interest in the subjects addressed.